Sermonix Pharmaceuticals is a privately held biotechnology company based in Columbus, OH, specializing in the development and commercialization of female-specific oncology products. Founded in 2014 by Dr. David Portman, a renowned clinical researcher and women's health expert, Sermonix Pharmaceuticals focuses on advancing treatments for breast and ovarian cancer, with a particular emphasis on the study of lasofoxifene.
The company is currently conducting the ELAINE Study, an open-label, randomized, multicenter trial that evaluates the efficacy of lasofoxifene compared to fulvestrant in the treatment of postmenopausal and premenopausal women with locally advanced or metastatic estrogen receptor-positive (ER+), human epidermal growth factor 2-negative (HER2-) breast cancer. Sermonix Pharmaceuticals is dedicated to providing innovative solutions for women's oncology and is actively involved in clinical research and collaborations with industry partners.
Generated from the website
